Ehealth Inc

This advisory Say-on-Pay proposal asks shareholders to approve the compensation disclosed for the Company’s Named Executive Officers. Management is seeking shareholder endorsement of a compensation program that emphasizes pay-for-performance, with a mix of base salary, a short-term annual bonus tied to operating cash flow, total revenue, adjusted EBITDA and specific FY25 operational priorities, and longer-term equity that is increasingly performance-based (PSUs tied to adjusted EBITDA margin) alongside RSUs for retention. The Compensation Committee engaged an independent consultant, reviewed peer data, and maintained a target bonus structure while shifting toward longer-term performance metrics and a three-year PSU performance period to strengthen alignment with sustained profitability. The board frames the program as necessary both to recruit and retain executives and to reward achievements, citing FY2025 outperformance on revenue and adjusted EBITDA while noting cash flow challenges; the Committee also approved certain transition and retention payments in connection with the CEO succession. As an advisory vote, the outcome is non-binding but the Board intends to consider the result in future compensation decisions; significant shareholder opposition could pressure changes to incentive design or governance practices. Potential investor concerns include founder/insider retention awards, sign-on and retention cash or equity given leadership transitions, and the dilution and accounting impact of equity grants, though management highlights steps taken to manage burn rates and discipline equity usage. Overall, the proposal invites shareholders to endorse the Committee’s view that the current mix and performance metrics appropriately balance short-term operational objectives and long-term value creation while preserving incentives for management to improve cash flow and margins.

This management proposal requests shareholder approval to add 1,300,000 shares to the Company’s 2024 Equity Incentive Plan, representing approximately a 4.1% dilutive impact on a fully diluted basis. Management argues the increase is necessary to support recruiting, retention and long‑term incentive grants through the 2027 grant cycle, citing historical usage, projected cancellations and forfeitures, and efforts to constrain equity burn. The board emphasizes a disciplined approach—requesting a relatively small, incremental increase rather than a large multi‑year authorization—and highlights governance features retained in the plan (minimum vesting, clawback provisions, independent committee administration, non‑employee director limits and no repricing without stockholder approval). The Compensation Committee reviewed gross and net burn rates, compared them to a healthcare/insuretech peer group, and concluded the company’s net burn is within a reasonable range given recent leadership transitions. Key investor considerations include dilution (current overhang ~15.7% projected to ~19.8% post‑approval), the company’s recent elevated grants to recruit and retain senior hires (including the CEO’s initial package), and the board’s commitment to continued monitoring and requesting more frequent shareholder approvals to limit long‑term dilution. Approval would permit the company to continue granting performance‑based and retention equity awards that management contends are critical to executing strategy, while failure to approve would constrain equity award capacity and likely force increased cash compensation, which the board argues would be less desirable for stockholder value over time.